Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Showing posts with label research. Show all posts
Showing posts with label research. Show all posts

Tuesday, September 29, 2015

PCORI approves $83m for hepatitis C and other studies

The Patient-Centered Outcomes Research Institute (PCORI) has approved $83m to fund 26 patient-centered, comparative clinical effectiveness research (CER) studies on a range of conditions and patient populations.

About $29.5m will support studies on caring for people affected with hepatitis C virus (HCV). Awards totaling around $7.4m will fund research on rare conditions in response to PCORI's offer of a special pool of funding for supportingt rare disease research.

The HCV studies will include national advocacy organizations, professional associations, and stakeholder groups in their research design and implementation.

Read more....

Friday, January 23, 2015

NIH Announces Funding for New Technologies for Viral Hepatitis

The National Institutes of Health (NIH) has issued a funding opportunity announcement (FOA) to encourage small businesses to address viral hepatitis research opportunities delineated in the Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis (Action Plan) [PDF 2MB]. The announcement of a Small Business Innovation Research (SBIR) grant entitled New Technologies for Viral Hepatitis SBIR (R43/R44) is supported by 3 participating institutes: the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

The FOA “encourages small business establishments to submit applications that address any of the specific research topics in the updated Action Plan for the Prevention, Care & Treatment of Viral Hepatitis that are assigned to the NIH and germane to the research mission of the respective NIH Institutes and Centers, in order to facilitate the development, evaluation, and validation of products that would be implemented in the public health efforts to reduce the burden of viral hepatitis in the United States.” Research objectives and strategies from the Action Plan that are relevant to this FOA include (but are not limited to) the development of: rapid screening tests, new diagnostic tests, tests for viral hepatitis-related complications, practical models of care, new and improved therapies to treat viral hepatitis or manage complications of disease or antiviral treatment, genetic-based tests for patient management or treatment selection, preventive vaccines, innovative approaches to pathogen identification and reduction in blood products.

Eligible applications include: new applications (Phase I, Fast-Track), renewals (Phase II), resubmissions (all phases), Phase IIB competing renewals, and revisions. Award amounts and durations are limited to 6 months and $150,000 for Phase I grants, and 2 years and $1,000,000 for Phase II grants. This FOA will be open for submissions beginning March 5, 2015.

Read more...